• FDA Puts Hold on Gilead’s Blood Cancer Therapy Trials

  • Feb 8 2024
  • Length: Less than 1 minute
  • Podcast

FDA Puts Hold on Gilead’s Blood Cancer Therapy Trials

Listen for free

View show details

  • Summary

  • The FDA has halted trials for Gilead’s blood cancer therapy due to an increased risk of patient death. This article covers the implications for Gilead Sciences, the drug magrolimab, and the broader landscape of similar treatments in development. Find out more on FinanceVoyager
    Show More Show Less
Show More Show Less

What listeners say about FDA Puts Hold on Gilead’s Blood Cancer Therapy Trials

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available